Elite outlines 2028 anticoagulant launch target as NASDAQ uplisting progresses (OTCMKTS:ELTP)
· seekingalpha.com
Elite Pharma (ELTP) Q1 FY2027 earnings call: steady $32.4M revenue, pipeline updates, FDA risks, NASDAQ uplisting timing, and tariff tailwinds—read now.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...